INTRODUCTION
============

Lung cancer has poor prognosis with only 15% of 5-yr survival rate. The treatment of lung cancer is a local removal with surgery or radiotherapy if it is indicated ([@B1]). The assessment of mediastinal lymph nodes (LNs) in lung cancer is a critical step of deciding whether surgical resection is appropriate or not. The use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is on the increase because of an accuracy and minimal invasiveness in accessing mediastinal LNs ([@B2]). Before performing EBUS-TBNA, standard bronchoscopy is usually done to identify any endobronchial lesion. In addition, bronchoscopy is generally performed during the evaluation of lung cancer stage based on the National Comprehensive Cancer Network (NCCN) guidelines ([@B1]). Bronchial anthracofibrosis (BAF) is a bronchoscopically visible anthracotic pigmentation associated with the narrowing or obliteration of the bronchi. As a bronchoscopy or EBUS-TBNA is widely performed, a detection of BAF becomes easier and more frequent. However, clinical implication of BAF is not completely understood.

BAF is considered to be associated with chronic biomass-fuel smoke exposure as well as active or old tuberculosis ([@B3], [@B4]). Because Korea is an endemic area of tuberculosis, BAF is frequently found during bronchoscopy or EBUS. Although a large scale investigation has not be done, Jang et al. ([@B5]) reported the prevalence of anthracofibrosis as 4.2% among the all patients who underwent a bronchoscopy. Mediastinal lymphadenopathy with calcification is a common co-existing CT finding of BAF ([@B3], [@B6], [@B7]) and false positive Positron emission tomography with 2-\[^18^F\] fluoro-2-deoxy-*D*-glucose as a tracer (FDG-PET) uptake is also frequently found in anthracosis. These finding often mimic a metastatic lymphadenopathy seen in lung cancer ([@B8]-[@B11]).

The aim of this study is to define the clinical significance of BAF and its role in the prediction of metastatic lymphadenopathy in lung cancer patients.

MATERIALS AND METHODS
=====================

This study was a retrospective review of a prospectively maintained research database of \"Bronchoscopy of the Asan Medical Center\" in Seoul, Korea. We selected patients who underwent EBUS-TBNA and diagnosed with lung cancer from May 2009 to August 2011. The diagnosis of lung cancer was made by pathological evidences; and the purpose of EBUS-TBNA was to assess a mediastinal staging (stage I to IIIB) or tissue confirmation (stage IV), like other institutes ([@B2]).

Their demographic features and clinical data were retrieved from the database and their electronic medical records (EMR). Demographic features included age, sex, clinical stage of lung cancer, target LNs, size of LNs, pathological findings of LNs from EBUS-TBNA and/or surgery, image findings of chest CT, bronchoscopy, EBUS-TBNA, and FDG-PET. BAF on bronchosocpy, aspirated tissue pigmentation for EBUS-TBNA, and standardized uptake value (SUV) for FDG-PET were checked. Lung cancer stage was determined according to TNM 7th edition. BAF and pigmentation of the EBUS-TBNA tissue were evaluated macroscopically by bronchoscopists ([@B4]) and the representative images are shown in [Fig. 1A](#F1){ref-type="fig"} (bronchial anthracofibrosis) and [1B](#F1){ref-type="fig"} (macroscopic pigmentation of the EBUS-TBNA tissue).

Statistical analyses
--------------------

Statistical analyses were performed with SPSS software version 18.0 (SPSS, Chicago, IL, USA). The Student\'s t-test was used for comparison of continuous variables and predicting indicators for malignant LN were analyzed by uni- and multivariate analyses.

Ethics statement
----------------

This study protocol was approved by the institutional review board of Asan Medical Center (IRB No.2012-0852). Informed consent was waived by the board.

RESULTS
=======

The clinical characteristics of total of 536 lung cancer patients are shown in [Table 1](#T1){ref-type="table"}. Of the 536 patients, 110 patients underwent surgical resection. Mean age was 64 yr (range: 29-85 yr), and 415 patients (77.4%) were male. Of these patients, 245 patients were diagnosed with adenocarcinoma (45.7%), 143 patients with squamous cell carcinoma (26.7%), 109 patients with small cell carcinoma (20.3%), 35 patients with other forms of non-small cell lung cancer (6.5%), and 4 patients with a combination of small cell carcinoma/non-small cell lung cancer (0.7%). BAF was observed in 55 patients (10.3%).

The characteristics of total 790 LNs are shown in [Table 2](#T2){ref-type="table"}. Malignant LN or reactive LN in EBUS-TBNA was defined according to the pathologic findings of biopsy or aspiration tissue. Of them, 527 LNs were malignant (66.7%) and 263 LNs were reactive (33.3%). Among the 263 reactive LNs, 69 LNs were resected by surgery and 92.8% of resected LNs were confirmed as reactive. The most frequently examined LN included 4R (30.3%), 7 (29.9%), and 4L (13.0%). The mean size of LN was 18.1 ± 10.0 mm and mean SUV was 6.6 ± 4.9. Pigmentation of EBUS-TBNA tissue was observed in 228 patients (28.9%) and BAF was observed in 92 LNs (11.6%) during bronchoscopy.

The comparison of LN characteristics between malignant LN and reactive LN is shown in [Table 3](#T3){ref-type="table"}. The mean SUV of the malignant LN group was 8.1 ± 5.2, and the mean SUV of the reactive LN group was 3.7 ± 2.6 (mean difference: 4.4; *P* \< 0.001). The mean size of the malignant LN group was 20.7 ± 10.2 mm, and the mean size of the reactive LN group was 12.9 ± 7.3 mm (mean difference: 7.9 mm; *P* \< 0.001). Pigmentation of EBUS-TBNA tissue was observed in 14.4% of malignant LNs, which was significantly lower than that of reactive LNs, 57.8%. BAF was also observed less frequently in malignant LNs than in reactive LNs, 5.3% and 24.3%, respectively. More detailed analyses according to tissue type of primary lung cancer, BAF in malignant LNs or reactive LNs are shown in [Tables 4](#T4){ref-type="table"}-[6](#T6){ref-type="table"}.

The relative risks for developing malignant LN were 3.3 (95% confidence interval \[CI\], 2.1-5.1; *P* \< 0.001) for LN ≥ 1 cm in size, 1.8 (95% CI, 1.5-2.3; *P* \< 0.001) for SUV ≥ 2.5, 0.4 (95% CI, 0.3-0.6; *P* \< 0.001) for macroscopic tissue pigmentation, and 0.4 (95% CI, 0.3-0.6; *P* \< 0.001) for BAF. There was no significant difference in terms of sex.

The adjusted odds ratio for malignant LN was 0.46 (95% CI, 0.26-0.81; *P* \< 0.001) for BAF, and 0.22 (95% CI, 0.15-0.33; *P* \< 0.001) for pigmentation of EBUS-TBNA tissue ([Table 7](#T7){ref-type="table"}) after adjusting an age, tissue type (NSCLC in contrast to SCLC), LN size (≥10 mm), and SUV (≥2.5). The specificities of pigmentation of EBUS-TBNA tissue and BAF for predicting a malignant LN were 42.2% and 75.7%, respectively, which was higher than the specificities of LN size ≥10 mm or SUV ≥2.5 ([Table 8](#T8){ref-type="table"}).

DISCUSSION
==========

The effort to defining morphologic and sonographic features of EBUS has become more pronounced according to the increased performance of EBUS. Fujiwara et al. ([@B12]) described in 2010 that features of malignant LNs are round shape, distinct margin, heterogeneous echogenicity, and presence of coagulation necrosis sign. Thereafter, Nguyen et al. ([@B13]) reported EBUS digital images of lymph nodes can be used to differentiate malignant and benign lymphadenopathy. However, there are little reports about relationship between anthracofibrosis and metastatic LNs in EBUS-TBNA.

LN size and SUV on FDG-PET are known parameters for predicting metastatic lymphadenopathy in lung cancer patients ([@B14]). We analyzed the relative risk of LN size and SUV on FDG-PET for predicting malignant LN in lung cancer patients. As expected, an LN ≥10 mm in size tended to be malignant by 3.3-fold and SUV ≥2.5 by 2.5-fold. Also, the odds ratio of a larger LN (ie, LN ≥10 mm in size) developing malignancy was 9.99 compared with smaller LN with an odds ratio of 3.59 when the SUV was large (ie, SUV ≥2.5). The sensitivity of LN size and SUV for the diagnosis of malignant LN was excellent (\>90%). However, their specificities were quite low: 20.5% and 27% for LN size and SUV, respectively.

BAF and pigmentation of aspirated tissue are observed easily during EBUS-TBNA, and those bronchoscopic findings can be identified by bronchoscopists without substantial error. However, their clinical implications are not appropriately explained during lung cancer work-up. Here, we showed higher specificities of BAF and macroscopic tissue pigmentation, 42.2% and 75.7%, respectively, than that of LN size and SUV despite of low sensitivities for the diagnosis of malignant LN. Multivariate analysis showed that the odds ratio of BAF and macroscopic tissue pigmentation was 0.46 and 0.22, respectively, which means that malignant LN shows less macroscopic tissue pigmentation and less BAF after consideration of age, tissue type, LN size, and SUV. According to the analyzed results, suggestive findings of malignant LNs are 1) younger age, 2) tissue type of SCLC, 3) LN size greater than 10 mm, 4) SUV greater than 2.5, 5) absence of BAF during bronchoscopy, and 6) absence of macroscopic tissue pigmentation during EBUS-TBNA.

There are some limitations about our study such as, retrospective design, absence of surgical confirmation of all LNs, and low sensitivity. In spite of these limitations, we try to attach a clinical implication to the BAF and macroscopic tissue pigmentation, which are occasionally inspected during EBUS-TBNA. Also, to the best of our knowledge, this is the first study to attach a clinical interpretation to BAF and tissue pigmentation in EBUS-TBNA.

Because Korea is an endemic area of tuberculosis, BAF is frequently observed and LN enlargement and false-positive FDG-PET SUV uptake mimic the mediastinal LN stage of lung cancer ([@B8]). We observed more frequent BAF or tissue pigmentation in reactive LN and proposed an additional interpretation of BAF and tissue pigmentation during EBNUS-TBNA. Putting BAF and macroscopic tissue pigmentation together with LN size and SUV, more reliable prediction would be possible before tissue confirmation.
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Clinical characteristics of patients (n = 536)
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NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; BAF, bronchial anthracofibrosis.
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Characteristics of lymph nodes (n = 790)
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LN, lymph node; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SUV, standardized uptake value; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; BAF, bronchial anthracofibrosis.
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Comparison of LN characteristics between malignant LN and reactive LN
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LN, lymph node; SUV, standardized uptake value; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; BAF, bronchial anthracofibrosis.
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Comparison of LN characteristics between tissue type of primary lung cancer
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Comparison of LN characteristics between BAF positive or negative in malignant LN
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Comparison of LN characteristics between BAF positive or negative in reactive LN
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###### 

Logistic regression of parameters associated with malignant LNs (n = 720)
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LN, lymph node; SUV, standardized uptake value; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; BAF, bronchial anthracofibrosis; OR, odds ratio.
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Diagnostic value of predicting malignant LNs
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LN, lymph node; SUV, standardized uptake value; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; BAF, bronchial anthracofibrosis; PPV, positive predictive value; NPV, negative predictive value.
